ImportRefusal LogoImportRefusal

Merck Kommanditgesellschaft auf Aktien

⚠️ High Risk

FEI: 3002806906 • Darmstadt, Hassia • GERMANY

FEI

FEI Number

3002806906

📍

Location

Darmstadt, Hassia

🇩🇪

Country

GERMANY
🏢

Address

Frankfurter Str. 250, , Darmstadt, Hassia, Germany

High Risk

FDA Import Risk Assessment

74.0
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

68
Total Refusals
7
Unique Violations
11/21/2025
Latest Refusal
10/15/2001
Earliest Refusal

Score Breakdown

Violation Severity
78.3×40%
Refusal Volume
68.1×30%
Recency
97.3×20%
Frequency
28.2×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7553×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

11814×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

166×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

32802×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

4821×

NUTRIT LBL

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.

4831×

DRUG NAME

The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.

3241×

NO ENGLISH

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).

Refusal History

DateProductViolationsDivision
11/21/2025
62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/20/2024
62ODY18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/16/2024
62ODB18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/28/2023
66JAY01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/28/2023
66JAY01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/24/2023
60LBC01ACETAMINOPHEN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/24/2023
66JDC01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/13/2023
66PAS99ULTRAVIOLET SCREEN/SUNSCREEN N.E.C.
118NOT LISTED
Division of Southeast Imports (DSEI)
11/10/2022
55RP99PHARMACEUTIC NECESSITIES, N.E.C.
118NOT LISTED
Division of Southeast Imports (DSEI)
8/26/2022
66JCC01LEVOTHYROXINE SODIUM (THYROID HORMONE)
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/10/2022
66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/22/2022
64MDB13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/10/2022
64MDY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/10/2022
64MCY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/3/2022
64MCY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/11/2022
64MDL13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/6/2022
64MCY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/1/2022
60SCH99ANTACID, N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/20/2021
66JCY01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/16/2021
62ODA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/8/2021
64RDY21SOMATROPIN (HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/29/2021
64MDY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/27/2020
66JAB01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/15/2020
66JDY01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/10/2020
66JCY01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/16/2020
62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/2/2020
62ODY18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/29/2020
62OCB18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/18/2020
62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Northern Border Imports (DNBI)
5/12/2020
62OCB18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
3280FRNMFGREG
Division of Southeast Imports (DSEI)
3/27/2020
66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/26/2019
64MCY07FOLLISTIM (FOLLITROPIN BETA(RDNA)) (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/1/2018
61PDY55METFORMIN HCL (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/8/2018
62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/14/2016
66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Florida District Office (FLA-DO)
7/28/2016
62WAS14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT)
118NOT LISTED
16DIRECTIONS
Philadelphia District Office (PHI-DO)
7/28/2016
62ODA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Florida District Office (FLA-DO)
7/28/2016
61XCY15DEXBROMPHENIRAMINE MALEATE (ANTI-HISTAMINIC)
75UNAPPROVED
Florida District Office (FLA-DO)
5/10/2016
62WBL14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT)
118NOT LISTED
75UNAPPROVED
Philadelphia District Office (PHI-DO)
5/10/2016
62WBL14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT)
118NOT LISTED
75UNAPPROVED
Philadelphia District Office (PHI-DO)
5/10/2016
62WBL14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT)
118NOT LISTED
75UNAPPROVED
Philadelphia District Office (PHI-DO)
3/17/2016
66VCB99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
Florida District Office (FLA-DO)
3/17/2016
66VCB99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
Florida District Office (FLA-DO)
3/10/2016
64XAR04RESORCINOL (KERATOLYTIC)
118NOT LISTED
16DIRECTIONS
Division of Northeast Imports (DNEI)
3/10/2016
65TAR04SULFUR (SCABICIDE)
118NOT LISTED
16DIRECTIONS
Division of Northeast Imports (DNEI)
2/1/2016
62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Cincinnati District Office (CIN-DO)
12/1/2015
66JAA01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Division of Northern Border Imports (DNBI)
11/9/2015
66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
Florida District Office (FLA-DO)
5/8/2015
62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Cincinnati District Office (CIN-DO)
1/26/2015
64MBY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE)
75UNAPPROVED
Cincinnati District Office (CIN-DO)
10/24/2014
54ADK05VITAMIN B12 (CYANOCOBALAMIN)
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/2/2014
64RCN21SOMATROPIN (HORMONE)
75UNAPPROVED
Division of Northeast Imports (DNEI)
4/11/2013
62CCA99ANTI-HYPERTENSIVE N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
6/18/2012
62MDO01CAMPHOR (ANTI-PRURITIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
12/13/2011
66JCB01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
New Orleans District Office (NOL-DO)
12/13/2011
66JCB01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
New Orleans District Office (NOL-DO)
9/9/2011
55RP99PHARMACEUTIC NECESSITIES, N.E.C.
483DRUG NAME
New Orleans District Office (NOL-DO)
6/25/2010
66VIP99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
New Orleans District Office (NOL-DO)
6/9/2010
65RAN01CALCIUM CHLORIDE (REPLENISHER)
16DIRECTIONS
New York District Office (NYK-DO)
3/12/2009
63XCS83MANNITOL (DIAGNOSTIC AID) (DRUGS)
75UNAPPROVED
New York District Office (NYK-DO)
8/7/2007
62ODC18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
New York District Office (NYK-DO)
6/17/2007
62YCB07MELOXICAM (ANTI-INFLAMMATORY, PART II)
75UNAPPROVED
New Orleans District Office (NOL-DO)
6/17/2007
62YCB07MELOXICAM (ANTI-INFLAMMATORY, PART II)
75UNAPPROVED
New Orleans District Office (NOL-DO)
5/22/2007
66VIP99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/8/2006
66PAS99ULTRAVIOLET SCREEN/SUNSCREEN N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
7/14/2006
64AAS08FORMALDEHYDE SOL (DISINFECTANT)
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)
6/28/2005
54ACA90MULTIPLE VITAMINS (MVI-12 VITAMIN COMBO) (VITAMIN)
324NO ENGLISH
482NUTRIT LBL
New Orleans District Office (NOL-DO)
10/15/2001
88LDTREAGENT, GENERAL PURPOSE
118NOT LISTED
New Orleans District Office (NOL-DO)

Frequently Asked Questions

What is Merck Kommanditgesellschaft auf Aktien's FDA import refusal history?

Merck Kommanditgesellschaft auf Aktien (FEI: 3002806906) has 68 FDA import refusal record(s) in our database, spanning from 10/15/2001 to 11/21/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Merck Kommanditgesellschaft auf Aktien's FEI number is 3002806906.

What types of violations has Merck Kommanditgesellschaft auf Aktien received?

Merck Kommanditgesellschaft auf Aktien has been cited for 7 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Merck Kommanditgesellschaft auf Aktien come from?

All FDA import refusal data for Merck Kommanditgesellschaft auf Aktien is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.